Takeda Pharmaceutical Co., Ltd. (TAK)
20.24
-0.12
(-0.59%)
USD |
NYSE |
Oct 23, 16:00
20.24
0.00 (0.00%)
After-Hours: 20:00
Takeda Pharmaceutical Enterprise Value : 91.54B for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 91.54B |
| October 22, 2026 | 91.91B |
| October 21, 2026 | 90.56B |
| October 20, 2026 | 91.03B |
| October 19, 2026 | 89.54B |
| October 16, 2026 | 89.73B |
| October 15, 2026 | 89.04B |
| October 14, 2026 | 87.65B |
| October 13, 2026 | 86.10B |
| October 12, 2026 | 86.60B |
| October 09, 2026 | 86.76B |
| October 08, 2026 | 86.10B |
| October 07, 2026 | 85.62B |
| October 06, 2026 | 84.77B |
| October 05, 2026 | 83.86B |
| October 02, 2026 | 84.01B |
| October 01, 2026 | 84.01B |
| September 30, 2026 | 85.06B |
| September 29, 2026 | 86.07B |
| September 28, 2026 | 87.30B |
| September 25, 2026 | 87.17B |
| September 24, 2026 | 86.32B |
| September 23, 2026 | 87.02B |
| September 22, 2026 | 87.46B |
| September 21, 2026 | 87.27B |
| Date | Value |
|---|---|
| September 18, 2026 | 87.33B |
| September 17, 2026 | 87.77B |
| September 16, 2026 | 86.48B |
| September 15, 2026 | 86.67B |
| September 14, 2026 | 86.35B |
| September 11, 2026 | 85.28B |
| September 10, 2026 | 84.80B |
| September 09, 2026 | 85.12B |
| September 08, 2026 | 85.47B |
| September 04, 2026 | 85.88B |
| September 03, 2026 | 86.70B |
| September 02, 2026 | 85.81B |
| September 01, 2026 | 85.18B |
| August 31, 2026 | 84.39B |
| August 28, 2026 | 84.55B |
| August 27, 2026 | 84.55B |
| August 26, 2026 | 85.18B |
| August 25, 2026 | 85.56B |
| August 24, 2026 | 85.21B |
| August 21, 2026 | 85.02B |
| August 20, 2026 | 84.87B |
| August 19, 2026 | 85.53B |
| August 18, 2026 | 84.61B |
| August 17, 2026 | 82.50B |
| August 14, 2026 | 83.29B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Sanofi | 110.23B |
| Dr. Reddy's Laboratories Ltd. | 11.00B |
| AstraZeneca PLC | 558.20B |
| Daiichi Sankyo Co., Ltd. | 31.63B |
| Eisai Co., Ltd. | 9.101B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 710.72M |
| Revenue (Quarterly) | 7.655B |
| Total Expenses (Quarterly) | 6.945B |
| EPS Diluted (Quarterly) | 0.2213 |
| Gross Profit Margin (Quarterly) | 57.57% |
| Profit Margin (Quarterly) | 9.28% |
| Earnings Yield | -1.67% |
| Operating Earnings Yield | 7.09% |
| Normalized Earnings Yield | -0.8864 |